Dupixent continues to steal the show in Sanofi's second quarter results

28 July 2023
sanofi_large

French drugmaker Sanofi (Euronext: SAN) has reported net sales for the second quarter of 2023 of $9.9 billion euros ($10.9 billion), a 1.5% fall, with net income of 1.4 billion euros and earnings per share (EPS) of  1.15 euros.

Beating many analysts’ expectations, the results have encouraged the firm to raise its outlook for the year.

Sanofi now expects 2023 EPS to grow at a mid single-digit rate, an outcome which includes an approximately 400 million-euro boost from better-than-expected vaccines sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical